Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
- 5 April 2011
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 25 (7), 1207-1209
- https://doi.org/10.1038/leu.2011.63
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineBlood, 2011
- Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotypeLeukemia, 2010
- Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experienceBlood, 2010
- Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.Blood, 2009
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex KaryotypeJournal of Clinical Oncology, 2008
- Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcomeCancer, 2007